Prognostic value of E‑26 transformation‑specific‑related gene in prostate cancer based on immunohistochemistry analysis

Zhang,Yang; Tao,Jing; Wang,Rangrang; Xuan,Haojie; Chen,Zhihao; Xiao,Li; Ding,Haiyong; Sun,Zhongquan

doi:10.3892/ol.2023.13882

Prognostic value of E‑26 transformation‑specific‑related gene in prostate cancer based on immunohistochemistry analysis

Authors:
- Yang Zhang
- Jing Tao
- Rangrang Wang
- Haojie Xuan
- Zhihao Chen
- Li Xiao
- Haiyong Ding
- Zhongquan Sun
View Affiliations

Affiliations: Department of Urology, Huadong Hospital, Fudan University, Shanghai 200040, P.R. China, Department of Surgery, Huadong Hospital, Fudan University, Shanghai 200040, P.R. China, Department of Urology, Huadong Hospital, Fudan University, Shanghai 200040, P.R. China, Department of Pathology, Huadong Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: May 24, 2023 https://doi.org/10.3892/ol.2023.13882
Article Number: 296
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

E‑26 transformation‑specific‑related gene (ERG) has been implicated in prostate cancer; however, its prognostic role remains unclear. Therefore, the present study aimed to investigate the association of ERG with the prognosis after radical prostatectomy in patients with prostate cancer. Patient data were collected at the Huadong Hospital, affiliated with Fudan University, between January 2016 and March 2020. ERG protein expression was detected using immunohistochemistry. Independent‑sample t‑tests and χ² tests were used to evaluate prostate cancer prognosis depending on ERG levels. The Kaplan‑Meier method was used to estimate biochemical failure‑free survival (BFFS) and the log‑rank test was used to test the distribution. Prognostic factors were determined using Cox regression analysis. The median patient age was 69 years (range, 47‑82 years). The median prostate‑specific antigen (PSA) and free‑PSA levels before treatment were 9.58 ng/ml (range, 0.003‑187.400 ng/ml) and 1.13 ng/ml (range, 0.0059‑30.6100 ng/ml), respectively. ERG protein expression was positive in 43 (16.6%) and negative in 216 (83.4%) cases. The median follow‑up period and BFFS were 30 and 28 months, respectively. There was a significant difference in biochemical recurrence (P=0.017) between patients with positive and negative ERG expression. Patients with positive ERG expression had significantly worse BFFS curves compared with those with negative ERG expression (P=0.0038). In the multivariate Cox regression analysis, positive ERG expression was found to be an independent prognostic factor in patients with prostate cancer who underwent radical prostatectomy (hazard ratio, 4.08; 95% confidence interval, 2.03‑8.17; P=0.000074). In conclusion, positive ERG expression is an independent prognostic risk factor for prostate cancer. These findings may be valuable for improvements in the clinical application of ERG immunohistochemistry.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Cao W, Chen HD, Yu YW, Li N and Chen WQ: Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI
3	Leprince D, Gegonne A, Coll J, de Taisne C, Schneeberger A, Lagrou C and Stehelin D: A putative second cell-derived oncogene of the avian leukaemia retrovirus E26. Nature. 306:395–397. 1983. View Article : Google Scholar : PubMed/NCBI
4	Nunn MF, Seeburg PH, Moscovici C and Duesberg PH: Tripartite structure of the avian erythroblastosis virus E26 transforming gene. Nature. 306:391–395. 1983. View Article : Google Scholar : PubMed/NCBI
5	Sperone A, Dryden NH, Birdsey GM, Madden L, Johns M, Evans PC, Mason JC, Haskard DO, Boyle JJ, Paleolog EM and Randi AM: The transcription factor Erg inhibits vascular inflammation by repressing NF-kappaB activation and proinflammatory gene expression in endothelial cells. Arterioscler Thromb Vasc Biol. 31:142–150. 2011. View Article : Google Scholar : PubMed/NCBI
6	Yuan L, Le Bras A, Sacharidou A, Itagaki K, Zhan Y, Kondo M, Carman CV, Davis GE, Aird WC and Oettgen P: ETS-related gene (ERG) controls endothelial cell permeability via transcriptional regulation of the claudin 5 (CLDN5) gene. J Biol Chem. 287:6582–6591. 2012. View Article : Google Scholar : PubMed/NCBI
7	Birdsey GM, Dryden NH, Amsellem V, Gebhardt F, Sahnan K, Haskard DO, Dejana E, Mason JC and Randi AM: Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood. 111:3498–3506. 2008. View Article : Google Scholar : PubMed/NCBI
8	Vijayaraj P, Le Bras A, Mitchell N, Kondo M, Juliao S, Wasserman M, Beeler D, Spokes K, Aird WC, Baldwin HS and Oettgen P: Erg is a crucial regulator of endocardial-mesenchymal transformation during cardiac valve morphogenesis. Development. 139:3973–3985. 2012. View Article : Google Scholar : PubMed/NCBI
9	Tomlins SA, Rhodes DR, Perner S, Dhannasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 310:644–648. 2005. View Article : Google Scholar : PubMed/NCBI
10	Sedarsky J, Degon M, Srivastava S and Dobi A: Ethnicity and ERG frequency in prostate cancer. Nat Rev Urol. 15:125–131. 2018. View Article : Google Scholar : PubMed/NCBI
11	Salagierski M and Schalken JA: PCA3 and TMPRSS2-ERG: Promising biomarkers in prostate cancer diagnosis. Cancers (Basel). 2:1432–1440. 2010. View Article : Google Scholar : PubMed/NCBI
12	Saramäki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL and Visakorpi T: TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res. 14:3395–3400. 2008. View Article : Google Scholar : PubMed/NCBI
13	Brady L, Carlsson J, Baird AM, Casey O, Vlajnic T, Murchan P, Cormican D, Costigan D, Gray S, Sheils O, et al: Correlation of integrated ERG/PTEN assessment with biochemical recurrence in prostate cancer. Cancer Treat Res Commun. 29:1004512021. View Article : Google Scholar : PubMed/NCBI
14	Berg KD, Vainer B, Thomsen FB, Røder MA, Gerds TA, Toft BG, Brasso K and Iversen P: ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. Eur Urol. 66:851–860. 2014. View Article : Google Scholar : PubMed/NCBI
15	Kong DP, Chen R, Zhang CL, Zhang W, Xiao GA, Wang FB, Ta N, Gao X and Sun YH: Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: A large-sample study in Chinese people and a systematic review. Asian J Androl. 22:200–207. 2020. View Article : Google Scholar : PubMed/NCBI
16	Humphrey PA, Moch H, Cubilla AL, Ulbright TM and Reuter VE: The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: Prostate and bladder tumours. Eur Urol. 70:106–119. 2016. View Article : Google Scholar : PubMed/NCBI
17	Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW and Amin MB: Updates in the Eighth Edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 73:560–569. 2018. View Article : Google Scholar : PubMed/NCBI
18	Gębska E, Sikora-Żydek A, Michalski M, Reichman-Warmusz E, Kurek J, Dudek D, Skowron W, Jarząb J and Wojnicz R: Tissue hemostasis is shifted toward thrombogenesis in the psoriatic plaques. Pathol Res Pract. 213:1125–1129. 2017. View Article : Google Scholar : PubMed/NCBI
19	Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM and Rubin MA: TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol. 31:882–888. 2007. View Article : Google Scholar : PubMed/NCBI
20	Chen Y, Chi P, Rockowitz S, Iaquinta PJ, Shamu T, Shukla S, Gao D, Sirota I, Carver BS, Wongvipat J, et al: ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med. 19:1023–1029. 2013. View Article : Google Scholar : PubMed/NCBI
21	Wang Z, Wang Y, Zhang J, Hu Q, Zhi F, Zhang S, Mao D, Zhang Y and Liang H: Significance of the TMPRSS2:ERG gene fusion in prostate cancer. Mol Med Rep. 16:5450–5458. 2017. View Article : Google Scholar : PubMed/NCBI
22	Wei Y, Peng J, He S, Huang H, Lin L, Zhu Q, Ye L, Li T, Zhang X, Gao Y and Zheng X: miR-223-5p targeting ERG inhibits prostate cancer cell proliferation and migration. J Cancer. 11:4453–4463. 2020. View Article : Google Scholar : PubMed/NCBI
23	Shah RB: Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management. Adv Anat Pathol. 20:117–124. 2013. View Article : Google Scholar : PubMed/NCBI
24	Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland SJ, Zheng Y and Ye D: Epidemiology and genomics of prostate cancer in Asian men. Nat Rev Urol. 18:282–301. 2021. View Article : Google Scholar : PubMed/NCBI
25	Bastus NC, Boyd LK, Mao X, Stankiewicz E, Kudahetti SC, Oliver RT, Berney DM and Lu YJ: Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res. 70:9544–9548. 2010. View Article : Google Scholar : PubMed/NCBI
26	Nguyen PN, Violette P, Chan S, Tanguay S, Kassouf W, Aprikian A and Chen JZ: A panel of TMPRSS2:ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity. Eur Urol. 59:407–414. 2011. View Article : Google Scholar : PubMed/NCBI
27	Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, et al: Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: Results from a baseline analysis in the canary Prostate Active Surveillance Study. Clin Cancer Res. 19:2442–2450. 2013. View Article : Google Scholar : PubMed/NCBI
28	Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, Steiner MS and Rubin MA: TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol. 32:206–211. 2014. View Article : Google Scholar : PubMed/NCBI
29	Sisodiya SM: Precision medicine and therapies of the future. Epilepsia. 62 (Suppl 2):S90–S105. 2021. View Article : Google Scholar : PubMed/NCBI
30	Loibl S, Poortmans P, Morrow M, Denkert C and Curigliano G: Breast cancer. Lancet. 397:1750–1769. 2021. View Article : Google Scholar : PubMed/NCBI